Notice of Allowability	Application No.	Applicant(s)	Applicant(s)	
	10/669,217	ESMOND ET AL.	ESMOND ET AL.	
	Examiner	Art Unit		
	Vickie Kim	1618		
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commits GHTS. This application is and MPEP 1308.	in this application. If not includ nunication will be mailed in due subject to withdrawal from issu	led course THIS	
1. This communication is responsive to <u>supp. examiner's ame</u>	endment requested on 3/3/	05(see interview summary).		
2. The allowed claim(s) is/are <u>13,17-19 and 21</u> .				
3. The drawings filed on are accepted by the Examiner	г.			
 4. Acknowledgment is made of a claim for foreign priority una a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" on oted below. Failure to timely comply will result in ABANDONM 	been received. been received in Application cuments have been receive .	on No. <u>09/394,712</u> . ed in this national stage applica		
 THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give 6. CORRECTED DRAWINGS (as "replacement sheets") must 	es reason(s) why the oath on t be submitted.	r declaration is deficient.	NOTICE OF	
(a) \square including changes required by the Notice of Draftspers		w (PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date				
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	Amendment / Comment o	r in the Office action of		
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on t ne header according to 37 CI	he drawings in the front (not the FR 1.121(d).	e back) of	
7. DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F	SIT OF BIOLOGICAL MAT FOR THE DEPOSIT OF BIO	ERIAL must be submitted. I OLOGICAL MATERIAL.	Note the	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/06) Paper No./Mail Date 2038-9/04-2/1/05 and 09 ∫ 29/64. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview S Paper No. 8), 7. ⊠ Examiner's	nformal Patent Application (PTo- ummary (PTO-413), /Mail Date <u>2/3/05</u> . Amendment/Comment Statement of Reasons for Allo 	owance	
U.S. Patent and Trademark Office		PRIMARY KIM	<u> </u>	
PTOL-37 (Rev. 1-04) Notice of Allowability Part of Paper No./Mail Date 20050			Mail Date 20050416	

Application/Control Number: 10/669,217 Page 2

Art Unit: 1618

Supplemental Examiner's Amendment

1. The instant supplemental Office action supercedes any previous office action and thus, applicant should be respond according to the instant office action in timely manner.

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Acker, Deborah on 3/3/05.

- 3. The application has been amended as follows:
 - a. Cancel claim 15.
 - b. Rewrite the claim 13 as following:
- --- Claim 13. (amended third): A method for the treatment of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of an agent, wherein the agent is selected from chromium, insulin-like growth factor and a thiazolidinedione, which increases the insulin sensitivity of the human, and restricting the metabolizable carbohydrates in the diet of the human, wherein the metabolizable carbohydrates in the diet are limited to no more than about 55 grams per day. ----

Conclusion

4. The claims 13, 17-19 and 21 which were previously allowed are maintained as allowed.

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0953. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

V/ckie Kim

Primary Patent Examiner

April 18, 2005 Art unit 1618